KM Pharmaceutical: Q1 Sales 4.47B Won, Operating Loss 0.66B Won, Stock Consolidation Approved

Q1 2026: Sales 4.47B won, operating loss 0.66B won, net loss 0.83B won
FY2025: Sales 16.0B won, operating loss 2.9B won, net loss 4.0B won
Debt ratio 71.64% (vs 64.13% end 2025), net debt ratio 32.56% (vs 25.70%): financial health worsening
Total borrowings increased to 17.1B won (15.8B won)
Major shareholder Kang Il-mo holds 37.62%
Stock consolidation: 5 shares into 1 (par value 100→500 won), shares from 27,887,050 to 5,577,410
Continued loan impairment on related party Seokjeong Golf & Resort (10.4B won)
New businesses (bottled water, pet products) in progress but no significant revenue yet
No dividends; capital surplus used to cover accumulated losses